Meda Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Solna Sweden (2001)
Status: Acquired by Mylan (2016)

Organization Overview

First Clinical Trial
2001
NCT00977483
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Meda Phamaceuticals, Sr.Dir Medical and Scientific Affairs | Meda Pharmaceuticals | MEDA Pharma GmbH & Co. KG, Bad Homburg/Germany | Meda Pharma US

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Asthma (Phase 2)

Asthma, Exercise-Induced (Phase 2)

Atrial Fibrillation (Phase 4)

Back Pain (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Basal Cell (Phase 3)

Cervical Intraepithelial Neoplasia (Phase 3)

Common Cold (Phase 3)

Condylomata Acuminata (Phase 4)

Dermatitis (Phase 3)

Dermatitis, Atopic (Phase 3)

Diabetic Neuropathies (Phase 3)

Eczema (Phase 3)

Esophagitis (Phase 3)

Herpes Labialis (Phase 3)

Hutchinson's Melanotic Freckle (Phase 3)

Keratosis (Phase 4)

Keratosis, Actinic (Phase 4)

Lentigo (Phase 3)

Leukemia (Phase 4)

Leukemia, Myeloid (Phase 4)

Leukemia, Myeloid, Acute (Phase 4)

Low Back Pain (Phase 3)

Melanoma (Phase 3)

Polyneuropathies (Phase 3)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Perennial (Phase 3)

Rhinitis, Allergic, Seasonal (Phase 4)

Warts (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 46
  • # of Trial APIs: 23